Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment

Sanofi (EURONEXT: SAN and NASDAQ: SNY) and Teva Pharmaceuticals, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announce today a collaboration to co-develop and co-commercialize asset TEV’574, currently in Phase 2b clinical trials for the treatment of Ulcerative Colitis and Crohn’s Disease, two types of inflammatory bowel disease.

Type 2 diabetes prevention programs can work at large scale, study finds

LONDON — Clinical trials have shown that lifestyle programs — which include diet, exercise, and behavioral coaching — can help people in danger of developing

November 15, 2023

RSV can be life-threatening for some people: Study

Every year, respiratory syncytial viruses (RSV) cause countless respiratory infections worldwide. For infants, young children and people with preexisting conditions, the virus can be life-threatening.

September 4, 2023

Combining ezetimibe and bempedoic acid effectively lowers cholesterol in statin-intolerant patients

A simulation study analyzing over two million German outpatients found that combining ezetimibe and bempedoic acid effectively reduces LDL cholesterol in statin-intolerant patients with hypercholesterolemia.

January 8, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.